Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (alveolar cells type 2) | 0.10 |
| chemistry Open Targets | compounds already reach it: olodanrigan | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 302 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4494
Sealed predictions
- AGTR2 in dopamine neurons, braak+0.22 (p 0.569) → +0.41 (p 0.273)receipt 4503
Swarm cases
receipt 4503: AGTR2 in dopamine neurons, braak
- power
- full sample +0.29 (p 0.246, n 18), 95% CI -0.21 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.64 (p 0.0042, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.66 (p 0.0030, n 18). not the mix.
- skeptic
- leave-one-out range +0.18 to +0.40, sign flips 0; without severely affected donors +0.29 (p 0.246, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AGTR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts